Midwest Professional Planners LTD. Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Midwest Professional Planners LTD. boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,784 shares of the medical research company’s stock after buying an additional 2,343 shares during the quarter. Midwest Professional Planners LTD.’s holdings in Edwards Lifesciences were worth $2,723,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Wellington Management Group LLP raised its position in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the last quarter. State Street Corp raised its position in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares during the last quarter. Geode Capital Management LLC raised its position in Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after buying an additional 284,918 shares during the last quarter. Fisher Asset Management LLC raised its position in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $555,939,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,803 shares of company stock worth $3,900,976. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EW. Citigroup upped their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price target for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Down 0.9 %

EW stock opened at $67.92 on Friday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $39.93 billion, a price-to-earnings ratio of 9.74, a PEG ratio of 4.82 and a beta of 1.12. The business has a 50 day simple moving average of $71.83 and a two-hundred day simple moving average of $70.32.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.